ContextVision Framtida tillväxt
Future kriterier kontrolleras 3/6
ContextVision förväntas öka intäkter och intäkter med 41.2% respektive 1.8% per år. EPS förväntas tillväxt med 42.4% per år. Avkastningen på eget kapital förväntas bli 12.7% om 3 år.
Viktig information
41.2%
Tillväxttakt i vinsten
42.41%
Tillväxttakt för EPS
| Healthcare Services vinsttillväxt | 24.7% |
| Intäkternas tillväxttakt | 1.8% |
| Framtida avkastning på eget kapital | 12.65% |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 25 Feb 2026 |
Senaste uppdateringarna om framtida tillväxt
Analysartikel • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Analysartikel • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Recent updates
Uppdatering av berättelse • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Uppdatering av berättelse • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Uppdatering av berättelse • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Uppdatering av berättelse • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Uppdatering av berättelse • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Uppdatering av berättelse • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).Uppdatering av berättelse • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).Uppdatering av berättelse • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.Uppdatering av berättelse • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.Uppdatering av berättelse • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.Uppdatering av berättelse • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.Analysartikel • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...Uppdatering av berättelse • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.Analysartikel • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Analysartikel • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...Analysartikel • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Uppdatering av berättelse • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).Analysartikel • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...Analysartikel • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
Ny berättelse • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Analysartikel • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...Analysartikel • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...Analysartikel • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...Analysartikel • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...Analysartikel • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...Analysartikel • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...Analysartikel • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...Analysartikel • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 118 | 16 | 16 | 23 | 1 |
| 12/31/2027 | 116 | 12 | 12 | 19 | 1 |
| 12/31/2026 | 113 | 8 | 10 | 16 | 1 |
| 3/31/2026 | 113 | 5 | 5 | 8 | N/A |
| 12/31/2025 | 111 | 1 | 0 | 4 | N/A |
| 9/30/2025 | 109 | 4 | 2 | 9 | N/A |
| 6/30/2025 | 116 | 9 | 6 | 14 | N/A |
| 3/31/2025 | 120 | 13 | 19 | 26 | N/A |
| 12/31/2024 | 131 | 25 | 29 | 33 | N/A |
| 9/30/2024 | 135 | 22 | 30 | 30 | N/A |
| 6/30/2024 | 138 | 26 | 35 | 36 | N/A |
| 3/31/2024 | 138 | 33 | 42 | 43 | N/A |
| 12/31/2023 | 133 | 33 | 44 | 45 | N/A |
| 9/30/2023 | 135 | 37 | 40 | 44 | N/A |
| 6/30/2023 | 130 | 36 | 40 | 43 | N/A |
| 3/31/2023 | 128 | 36 | 36 | 40 | N/A |
| 12/31/2022 | 123 | 33 | 21 | 26 | N/A |
| 9/30/2022 | 117 | 34 | 18 | 25 | N/A |
| 6/30/2022 | 115 | 37 | 9 | 15 | N/A |
| 3/31/2022 | 106 | 35 | -4 | 2 | N/A |
| 12/31/2021 | 100 | 35 | 5 | 9 | N/A |
| 9/30/2021 | 94 | 53 | 8 | 8 | N/A |
| 6/30/2021 | 90 | 42 | 10 | 11 | N/A |
| 3/31/2021 | 86 | 35 | 18 | 23 | N/A |
| 12/31/2020 | 95 | 38 | 14 | 22 | N/A |
| 9/30/2020 | 99 | 8 | 11 | 23 | N/A |
| 6/30/2020 | 100 | 10 | 9 | 26 | N/A |
| 3/31/2020 | 103 | 13 | 0 | 20 | N/A |
| 12/31/2019 | 95 | 7 | N/A | 25 | N/A |
| 9/30/2019 | 95 | 14 | N/A | 22 | N/A |
| 6/30/2019 | 94 | 11 | N/A | 24 | N/A |
| 3/31/2019 | 93 | 5 | N/A | 11 | N/A |
| 12/31/2018 | 91 | -1 | N/A | 5 | N/A |
| 9/30/2018 | 85 | -2 | N/A | 5 | N/A |
| 6/30/2018 | 82 | -3 | N/A | 5 | N/A |
| 3/31/2018 | 82 | -2 | N/A | 4 | N/A |
| 12/31/2017 | 81 | -2 | N/A | 2 | N/A |
| 9/30/2017 | 83 | -1 | N/A | 5 | N/A |
| 6/30/2017 | 85 | 1 | N/A | 1 | N/A |
| 3/31/2017 | 81 | 0 | N/A | 4 | N/A |
| 12/31/2016 | 82 | 4 | N/A | 10 | N/A |
| 9/30/2016 | 76 | 3 | N/A | 6 | N/A |
| 6/30/2016 | 73 | 4 | N/A | 10 | N/A |
| 3/31/2016 | 72 | 5 | N/A | 12 | N/A |
| 12/31/2015 | 72 | 5 | N/A | 9 | N/A |
| 9/30/2015 | 70 | 5 | N/A | 9 | N/A |
| 6/30/2015 | 67 | 4 | N/A | 10 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: CONTX s prognostiserade vinsttillväxt ( 41.2% per år) är över sparkvoten ( 3.3% ).
Resultat vs marknad: CONTX s intäkter ( 41.2% per år) förväntas växa snabbare än marknaden för Norwegian ( 10.1% per år).
Höga tillväxtresultat: CONTX s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: CONTX s intäkter ( 1.8% per år) förväntas växa långsammare än marknaden för Norwegian ( 2.5% per år).
Hög tillväxtintäkter: CONTX s intäkter ( 1.8% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: CONTX s avkastning på eget kapital förväntas bli låg om 3 år ( 12.7 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/31 09:53 |
| Aktiekurs vid dagens slut | 2026/05/29 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ContextVision AB (publ) bevakas av 3 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |